Daily Carnosine and Anserine Supplementation Alters Verbal Episodic Memory and Resting State Network Connectivity in Healthy Elderly Adults

Background: Intravenous Tissue Plasminogen Activator (TPA) is the only FDA approved medical therapy for acute ischemic stroke (AIS). Prior study suggests that early recanalization is associated with better stroke outcome. Our aim was to correlate task-negative and task-positive (TN/TP) resting state network activity with tissue perfusion and functional outcome, in stroke patients who received TPA. Method: AIS patients were consented and underwent NIH stroke scale (NIHSS) assessment and magnetic resonance imaging (MRI) scans during TPA infusion (baseline) and six hours post stroke. The MRI sequences include contrast-enhanced perfusion weighted image (PWI) and resting state Blood Oxygen Level-Dependent or BOLD (RSB) images acquired using a Siemens Treo 3T MRI scanner. Additionally, the RSB scan and the NIHSS were obtained at a 30-day follow up visit. Results: Fourteen patients (mean age ± SD=63 ±14, 50% male, 50% white, 43% black and 7% others) who qualified for TPA completed the study at baseline and 6 hours post stroke. Of these, 6 patients had valid follow up data at 30 days. Three patients without cerebral ischemia were excluded. A paired samples t-test comparing baseline and 6h post stroke showed a significantly improved TP network t(10)= -4.24 p< 0.05. The resting network connectivity improved from 6 hours post stroke to 30-days follow up, t(5)= -5.35 p< 0.01. Similarly, NIHSS, at 6h post stroke t(10)= 3.62 p< 0.01 and at 30-days follow up t(5)= -3.4 p< 0.01 were significantly better than the NIHSS at baseline. The 6-hours post-stroke perfusion correlated with the resting network connectivity in both the damaged (r=-0.56 p= 0.07) and intact hemispheres (r= -0.57 p= 0.06). Differences in functional connectivity and NIHSS scores from baseline to 6 h were positively correlated (r= 0.56 p=0.07). Conclusion: In this pilot study we found that TPA led to changes in MRI based resting state networks and associated functional outcome. Correlations were found between perfusion, functional connectivity and NIHSS. This suggests that the improvement of resting state network means improved efficiency of brain activity indicated by functional outcome and may be a potential predictive MRI biomarker for TPA response. A larger study is needed to verify this finding.

Download Full-text

Modifying the Brain’s Resting-State Network Connectivity with Near Infrared Transcranial Photobiomodulation

Brain Stimulation ◽

10.1016/j.brs.2018.12.482 ◽

2019 ◽

Vol 12 (2) ◽

pp. 456

Author(s):

R. Zomorrodi ◽

G. Loheswaran ◽

A. Pushparaj ◽

l Lim

Keyword(s):

Resting State ◽

Near Infrared ◽

Network Connectivity ◽

Resting State Network

Download Full-text

Altered resting-state network connectivity in stroke patients with and without apraxia of speech

NeuroImage Clinical ◽

10.1016/j.nicl.2015.03.013 ◽

2015 ◽

Vol 8 ◽

pp. 429-439 ◽

Cited By ~ 25

Author(s):

Anneliese B. New ◽

Donald A. Robin ◽

Amy L. Parkinson ◽

Joseph R. Duffy ◽

Malcom R. McNeil ◽

...

Keyword(s):

Resting State ◽

Network Connectivity ◽

Apraxia Of Speech ◽

Stroke Patients ◽

Resting State Network

Download Full-text

Non-invasive electrical stimulation of the brain (ESB) modifies the resting-state network connectivity of the primary motor cortex: A proof of concept fMRI study

Brain Research ◽

10.1016/j.brainres.2011.06.013 ◽

2011 ◽

Vol 1403 ◽

pp. 37-44 ◽

Cited By ~ 21

Author(s):

G. Alon ◽

S.R. Roys ◽

R.P. Gullapalli ◽

J.D. Greenspan

Keyword(s):

Electrical Stimulation ◽

Resting State ◽

Primary Motor Cortex ◽

Network Connectivity ◽

Proof Of Concept ◽

Non Invasive ◽

Resting State Network ◽

Fmri Study ◽

The Brain ◽

Stimulation Of

Download Full-text

Effects of dopamine agonist treatment on resting-state network connectivity in Parkinson’s disease

10.1101/2020.01.31.928853 ◽

2020 ◽

Author(s):

David M. Cole ◽

Bahram Mohammadi ◽

Maria Milenkova ◽

Katja Kollewe ◽

Christoph Schrader ◽

...

Keyword(s):

Parkinson’S Disease ◽

Decision Making ◽

Parkinson's Disease ◽

Basal Ganglia ◽

Dopamine Agonist ◽

Resting State ◽

Large Scale ◽

Network Connectivity ◽

Resting State Network ◽

Large Scale Networks

ABSTRACTDopamine agonist (DA) medications commonly used to treat, or ‘normalise’, motor symptoms of Parkinson’s disease (PD) may lead to cognitive-neuropsychiatric side effects, such as increased impulsivity in decision-making. Subject-dependent variation in the neural response to dopamine modulation within cortico-basal ganglia circuitry is thought to play a key role in these latter, non-motor DA effects. This neuroimaging study combined resting-state functional magnetic resonance imaging (fMRI) with DA modification in patients with idiopathic PD, investigating whether brain ‘resting-state network’ (RSN) functional connectivity metrics identify disease-relevant effects of dopamine on systems-level neural processing. By comparing patients both ‘On’ and ‘Off’ their DA medications with age-matched, un-medicated healthy control subjects (HCs), we identified multiple non-normalising DA effects on frontal and basal ganglia RSN cortico-subcortical connectivity patterns in PD. Only a single isolated, potentially ‘normalising’, DA effect on RSN connectivity in sensori-motor systems was observed, within cerebro-cerebellar neurocircuitry. Impulsivity in reward-based decision-making was positively correlated with ventral striatal connectivity within basal ganglia circuitry in HCs, but not in PD patients. Overall, we provide brain systems-level evidence for anomalous DA effects in PD on large-scale networks supporting cognition and motivated behaviour. Moreover, findings suggest that dysfunctional striatal and basal ganglia signalling patterns in PD are compensated for by increased recruitment of other cortico-subcortical and cerebro-cerebellar systems.

Download Full-text

Effect of Citicoline on Memory Function in Healthy Order Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Current Developments in Nutrition ◽

10.1093/cdn/nzaa057_043 ◽

2020 ◽

Vol 4 (Supplement_2) ◽

pp. 1227-1227

Author(s):

Eri Nakazaki ◽

Eunice Mah ◽

Danielle Citrolo ◽

Fumiko Watanabe

Keyword(s):

Adverse Events ◽

Episodic Memory ◽

Paired Associate ◽

Clinical Chemistry ◽

Memory Function ◽

Memory Loss ◽

Elderly Adults ◽

Double Blind ◽

Double Blind Placebo ◽

Healthy Elderly

Abstract Objectives Subtle deficits in memory in healthy elderly adults are considered to be a normal consequence of aging [i.e., age-associated memory impairment (AAMI)]. The prevalence of cognitive impairment without dementia in the elderly is estimated at 5.4 million, and every year roughly 12% of these individuals go on to develop dementia. Supplementation of citicoline (CDP-choline), a naturally occurring mononucleotide, has shown beneficial effects on memory function and behavior in populations with a wide range of impairments. Unfortunately, few studies have investigated the effects of citicoline supplementation on memory in healthy elderly adults with memory loss due to aging. Thus, the objective of this study was to investigate the effects of Cognizin®, a citicoline supplement, on memory in healthy elderly populations with AAMI. Methods A total of 100 healthy men and women between 50 to 85 years of age with AAMI participated in this randomized, double-blind, placebo-controlled trial. Subjects were randomized to receive placebo (n = 51) or Cognizin® (n = 49; 500 mg/day) for 12 weeks. Memory functions were assessed at baseline and end of the intervention (12 weeks) using computerized tests (Cambridge Brain Sciences, Ontario, Canada). Safety measurements included adverse events query, hematology and clinical chemistry. Results A total of 99 out of 100 subjects completed the study in its entirety. After the 12 week intervention, subjects supplemented with Cognizin® showed significantly greater improvements in episodic memory (assessed by the Paired Associate test) compared to those on placebo. Scores for composite memory, calculated using the scores of four memory tests (Spatial Span, Monkey Ladder, Paired Associate, and Digit Span) also improved to a greater extent following Cognizin® supplementation compared to placebo. There were no adverse events related to a study product and hematology and clinical chemistry were stable throughout the intervention. Conclusions Dietary supplement of Cognizin® for 12 weeks improved overall memory performance, especially episodic memory, in healthy males and females with AAMI. The findings suggest that regular consumption of Cognizin® may be safe and potentially beneficial against memory loss due to aging. Funding Sources Kyowa Hakko Bio Co., Ltd.

Download Full-text